Süleyman Atalay1, Belkıs Soylu2, Aslı Aykaç3, Ayliz Velioğlu Öğünç4, Şule Çetinel5, Naziye Özkan5, Can Erzik6, Ahmet Özer Şehirli7. 1. Department of General Surgery, Haydarpasa Numune Training and Research Hospital, İstanbul, Turkey. 2. Department of Pharmacology, Marmara University School of Pharmacy, İstanbul, Turkey. 3. Department of Biophysics, Near East University School of Medicine, Nicosia, Turkish Republic of Northern Cyprus. 4. Department of Biochemistry, Marmara University Vocational School of Health Related Professions, İstanbul, Turkey. 5. Department of Histology-Embryology, Marmara University School of Medicine, İstanbul, Turkey. 6. Department of Medical Biology, Marmara University School of Medicine, İstanbul, Turkey. 7. Department of Pharmacology, Near East University School of Dentistry, Nicosia, Turkish Republic of Northern Cyprus.
Abstract
OBJECTIVES: In the present study, it was aimed to study the antioxidant effects of spironolactone (SPL) to determine its possible protective effects in hepatic ischemia reperfusion injury. MATERIAL AND METHODS: Hepatic artery, portal vein, and bile duct of Wistar albino rats were clamped for 45 minutes under anesthesia to form an ischemia period. Then reperfusion was allowed and the rats were decapitated 60 minutes later. SPL (20 mg/kg, p.o.) or SF was orally administered for 30 minutes before ischemia. Rats in the control arm underwent sham surgery and were administered isotonic saline. Liver function was studied by measuring aspartate aminotransferase (AST), alanine aminotransferase (ALT), tumor necrosis factor-alpha (TNF-α), and interleukin 1beta (IL-1β) levels. Malondialdehyde (MDA), glutathione (GSH), luminol, and lucigenin levels, myeloperoxidase (MPO) and Na+-K+-ATPase enzyme activities were analyzed to study tissue injury under light microscope. RESULTS: While IR increased AST, ALT, TNF-α, and IL-1β levels and MDA, luminol, and lusigenin levels and MPO activities, it caused a decrease in GSH levels and Na+K+-ATPase activity. Spironolactone administration significantly improved these values. CONCLUSION: Protective effects of SPL against ischemia/reperfusion injury via various mechanisms suggest that this agent may become a novel treatment agent in clinical practice.
OBJECTIVES: In the present study, it was aimed to study the antioxidant effects of spironolactone (SPL) to determine its possible protective effects in hepatic ischemia reperfusion injury. MATERIAL AND METHODS: Hepatic artery, portal vein, and bile duct of Wistar albino rats were clamped for 45 minutes under anesthesia to form an ischemia period. Then reperfusion was allowed and the rats were decapitated 60 minutes later. SPL (20 mg/kg, p.o.) or SF was orally administered for 30 minutes before ischemia. Rats in the control arm underwent sham surgery and were administered isotonic saline. Liver function was studied by measuring aspartate aminotransferase (AST), alanine aminotransferase (ALT), tumor necrosis factor-alpha (TNF-α), and interleukin 1beta (IL-1β) levels. Malondialdehyde (MDA), glutathione (GSH), luminol, and lucigenin levels, myeloperoxidase (MPO) and Na+-K+-ATPase enzyme activities were analyzed to study tissue injury under light microscope. RESULTS: While IR increased AST, ALT, TNF-α, and IL-1β levels and MDA, luminol, and lusigenin levels and MPO activities, it caused a decrease in GSH levels and Na+K+-ATPase activity. Spironolactone administration significantly improved these values. CONCLUSION: Protective effects of SPL against ischemia/reperfusion injury via various mechanisms suggest that this agent may become a novel treatment agent in clinical practice.
Authors: Y Yabe; N Kobayashi; T Nishihashi; R Takahashi; M Nishikawa; Y Takakura; M Hashida Journal: J Pharmacol Exp Ther Date: 2001-09 Impact factor: 4.030
Authors: J S Silvestre; V Robert; B Escoubet; C Heymes; A Oubénaïssa; C Desopper; B Swynghedauw; C Delcayre Journal: J Mol Cell Cardiol Date: 2000-07 Impact factor: 5.000
Authors: Johan Denollet; Angélique A Schiffer; Martijn Kwaijtaal; Herbert Hooijkaas; Eric H Hendriks; Jos W Widdershoven; Nina Kupper Journal: Am J Cardiol Date: 2008-11-21 Impact factor: 2.778